Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
1. Emergent BioSolutions receives a $30 million BARDA contract modification for CYFENDUS®. 2. CYFENDUS® is an anthrax vaccine, delivery expected by March 2026. 3. The U.S. government prioritizes medical countermeasures against biological threats like anthrax. 4. Emergent's prior contract modification was for $50 million in December 2024. 5. The FDA approved CYFENDUS® for post-exposure prophylaxis in July 2023.